Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge

Author: Vandana Singh | June 07, 2024 11:58am

U.S. District Judge Karen Marston in Philadelphia is set to preside over litigation involving the popular diabetes and weight-loss drugs Ozempic, Wegovy, and Mounjaro.

The Judicial Panel on Multidistrict Litigation appointed Marston to manage over 10,000 personal injury lawsuits.

U.S. District Judge Gene E.K. Pratter, who had previously been handling the case, had died.

Marston, a former federal prosecutor appointed by Donald Trump in 2019, is expected to move swiftly.

Related: Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System.

The litigation centers on allegations that the drugmakers failed to warn about potential severe digestive side effects.

Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) deny the claims.

Marston’s new role comes at a time when one in eight U.S. adults are using GLP-1 class medications, making the case highly publicized.

The drugs are widely used for treating diabetes and weight loss, with plaintiffs alleging the drugs cause conditions such as gastroparesis, severe vomiting, and bowel obstruction.

A key task for Marston will be finalizing the plaintiff’s fact sheet, which will contain essential details on the claimants’ injuries, medical conditions, and drug use.

Defense counsel sees this as an opportunity to narrow the litigation, potentially eliminating claims involving counterfeit products or those without a proper diagnosis of gastroparesis.

However, plaintiffs’ lawyers oppose the premature dismissal of claims and seek additional discovery and bellwether trials to resolve the cases.

Read Next: Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns.

Price Action: NVO shares are up 0.49% at $143.10 at last check Friday.

Image: Shutterstock

Posted In: LLY NVO